Mayo Clinic · Rochester, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Latest publication · Nat Rev Clin Oncol, Jan 2026Diagnosis, risk stratification and management of smouldering multiple myeloma.
Research view
Multiple myeloma: who works on it
Groups that published on this disease or run trials on it, from public registries and publications. Researchers appear by name only once their profile is published.
Find fellow researchers
One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.
- All targets
- BCMA 134
- CD38 22
- GPRC5D 36
- CD19 31
- TP53 0
- STAT3 0
- CXCR4 4
- MYC 0
- BCL-2 2
- PI3K 1
- mTOR 0
- IL-6 0
- STING 0
- BRAF 2
- CD47 1
- HDAC 0
- AKT 0
- PD-1 1
- PD-L1 1
- CD20 3
- GLP-1 0
- JAK 0
- PTEN 0
- SGLT2 0
- AMPK 0
- B7-H3 0
- NRAS 1
- TIGIT 0
- CTLA-4 1
- ERK 0
- EZH2 0
- FTO 0
- IL-15 3
- JNK 0
- KRAS 1
- MAPK 0
- RAS 0
- CD22 2
- CD33 1
- CTNNB1 0
- EGFR 0
- FGFR 0
- LAG-3 0
- MDM2 0
- METTL3 0
- NRF2 0
- BRCA1 0
- BRD4 0
- BTK 1
- CD123 1
- CD30 0
- CDK4/6 0
- GPX4 0
- HER2 0
- HIF-1 0
- HSP90 0
- MEK 0
- MET 0
- MUC1 0
- NTRK 0
EU-13 is a filter, not a ranking: it only narrows the list.
New York, United States
Boston, United States
The University of Texas MD Anderson Cancer Center · Houston, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Latest publication · Eur J Haematol, Jan 2026Comparative Effectiveness and Safety of PI-Rd Triplets in Relapsed/Refractory Multiple Myeloma: INSIGHT-MM Data Analysis.
Würzburg, Germany
Moffitt Cancer Center · Tampa, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Latest publication · Blood Adv, Mar 2026Meaningful change in patient-reported outcomes after CAR-T for multiple myeloma: differences by race and ethnicity.
New York, United States
Pamplona, Spain
Cleveland, United States
Seattle, United States
Atlanta, United States
Milwaukee, United States
Birmingham, United States
Nantes, France
Hamburg, Germany
Duarte, United States
The University of Texas Southwestern Medical Center · Dallas, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Latest publication · Blood Cancer J, Jan 2026Peripheral blood immune cell profiling and response to BCMA CAR-T cell therapy in relapsed refractory multiple myeloma.
Amsterdam, Netherlands
Heidelberg, Germany
Beijing, China
Atlanta, United States
San Francisco, United States
Massachusetts General Hospital · Boston, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Latest publication · Leukemia, Dec 2025Prognostic value of serological and PET/CT response kinetics in patients with multiple myeloma treated with BCMA CAR-T.
University of Arkansas for Medical Sciences · Little Rock, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Latest publication · J Clin Oncol, Jan 2026Treatment of Multiple Myeloma: ASCO-Ontario Health (Cancer Care Ontario) Living Guideline.
24 of 99+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.
Who stopped a trial, and why
Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.
Suspended
“The collaborator EsoBiotec was acquired by AstraZeneca.”Registry text, quoted unchanged. Source
Terminated
BCMA-directed CAR-T Cell Therapy in Adult Patients With Multiple Myeloma
“Business decision”Registry text, quoted unchanged. Source
Terminated
Universal BCMA-targeted LUCAR-B68 Cells in Patients With Relapsed/Refractory Multiple Myeloma
“Achieved the proof of concept”Registry text, quoted unchanged. Source
Suspended
CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma
“Safety Review”Registry text, quoted unchanged. Source
Withdrawn
“Due to corporate strategic adjustment.”Registry text, quoted unchanged. Source
Withdrawn
BCMA/GPRC5D CAR-T Therapy for Multiple Myeloma
“Due to corporate strategic adjustment.”Registry text, quoted unchanged. Source
Withdrawn
UF-KURE-BCMA CAR-T Cells in Patients With Relapsed or Refractory Multiple Myeloma
“Replaced by study by different sponsor”Registry text, quoted unchanged. Source
Suspended
Universal CAR-T Cells (REVO-UWD-00B) for Refractory and Relapsed Multiple Myeloma
“Because the implementation of the new regulation policy by the Chinese authority”Registry text, quoted unchanged. Source
Withdrawn
BCMA CAR-T Cell Therapy in High-risk NDMM Patients With Positive MRD After First-line ASCT
“The study was withdrawn due to the inability to enroll participants.”Registry text, quoted unchanged. Source
Terminated
“A business decision was made by Pfizer to terminate the study and not proceed with the Phase 2 expansion of this study. The reason for study termination is not due to any safety concerns or requests from regulatory authorities.”Registry text, quoted unchanged. Source
Trials that share participant data
Trials whose registry record says individual participant data (IPD) will be shared.
Search by method
Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.
- Single-Cell Analysis 23
- Organoids 3
- Mendelian Randomization Analysis 10
- CRISPR-Cas Systems 8
- Gene Expression Profiling 44
- Sequence Analysis, RNA 7
- Whole Genome Sequencing 4
- Exome Sequencing 3
- Proteomics 15
- Metabolomics 10
- Mass Spectrometry 7
- Flow Cytometry 48
- Immunohistochemistry 11
- Liquid Biopsy 2
- Circulating Tumor DNA 2
- Xenograft Model Antitumor Assays 78
- Positron-Emission Tomography 14
- Magnetic Resonance Imaging 26
- Machine Learning 17
- Deep Learning 6
- Cohort Studies 32
- Genome-Wide Association Study 7
Paste an abstract
See which targets of this disease your abstract mentions, and go to the people working on them.
Matched in your browser only. The text is not sent, saved or logged.
Sources: ClinicalTrials.gov, EU CTR, OpenAlex, PubMed. Machine-matched links are labelled.